摘要
目的观察干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎的临床疗效。方法 42例小儿喘息性支气管炎患儿按照随机数表方法分为治疗组和对照组各21例。两组在常规治疗的基础上,治疗组加用干扰素α1b5万U/kg/d雾化吸入,并每晚口服孟鲁司特钠4mg;对照组给予利巴韦林10～15mg/kg静脉滴注,对比观察两组疗效。结果治疗组总有效率为95.2%,对照组总有效率为71.4%,两组总有效率比较差异有统计学意义(χ2=10.823,P<0.01),治疗组发热、喘鸣音等症状消失时间明显短于对照组(P<0.01)。结论干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎安全有效,值得临床推广应用。
Objective To observe the efficacy of the combined use of IFN α1b and montelukast sodium in treatment of children with asthmatic bronchitis. Methods 42 children with asthmatic bronchitis were randomly divided into two groups with 21 cases in each group. In addition to symptomatic treatment, IFN α1b5 × 10^4 U/kg qd and montelukast sodium 4mg,qn were administered in treatment group, while ribavirin was given at 10- 15mg/kg, qd in control group. Symptoms and signs were observed. Results The treatment efficiency was 95.2% in combined treatment group and 71.4 % in control group after one week treatment（X^22 = 10. 823 ,P〈0.01）. The time for pyrexia and wheeze disappearance in treatment group was shorter than that in control group （P〈0.01）. Conclusion The combined use of IFNα1b and montelukast sodium significantly improves symptoms, shortens the course of disease and increases cure rate without obvious adverse effect in the treatment of children with asthmatic bronchitis. The treatment schedule is worthy of being recommended for clinical application.
出处
《西部医学》
2012年第7期1358-1359,1361,共3页
Medical Journal of West China
